ApomorphineLevodopaAntiparkinson AgentsCarbidopaDopamine AgonistsParkinson DiseaseReceptors, DopamineDyskinesia, Drug-InducedBenserazideHaloperidolDihydroxyphenylalanineDopamine AgentsPiribedilDopamineEmeticsPenile ErectionAdministration, OralPimozideTrihexyphenidylDopamine AntagonistsStereotyped BehaviorParkinson Disease, SecondaryStartle ReactionErgolinesReceptors, Dopamine D2LisurideBromocriptineDose-Response Relationship, DrugCatalepsyBis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfideOxidopamineRats, Sprague-DawleyAdministration, SublingualMotor ActivityInjections, SubcutaneousTranquilizing AgentsCorpus StriatumSubthalamic NucleusBehavior, AnimalSensory GatingHydroxydopaminesInjections, IntravenousQuinpiroleTime FactorsParkinsonian DisordersInfusion PumpsDrug Administration ScheduleYawningSubstantia NigraDyskinesiasAmphetamineDomperidoneDrug Administration RoutesSelegilineRats, WistarReceptors, Dopamine D12,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepineBenzophenonesMetoclopramideDrug InteractionsBenzazepinesGlobus PallidusHarmineNeurologic ExaminationParkinson Disease, PostencephaliticMotor SkillsDopa DecarboxylaseHomovanillic AcidReceptors, Dopamine D3Movement DisordersBrainPenisChronotherapyDouble-Blind MethodCaudate NucleusSulpirideDystoniaRats, Inbred StrainsDisease Models, AnimalMuscle RigidityInjectionsSpiperoneInjections, IntraventricularErectile DysfunctionDrug Therapy, CombinationDeep Brain StimulationUnited States Food and Drug AdministrationOlivopontocerebellar AtrophiesMPTP PoisoningFlupenthixolInjections, IntraperitonealAntipsychotic AgentsBiological AvailabilityTremorCatechol O-MethyltransferaseCross-Over StudiesDrug CombinationsTreatment OutcomeAdministration, Intranasal